Showing results (111-120 of 169) with videos related to

Sort By:
Pageof 17
Molecular Cancer Therapeutics|November 2, 2021
Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal CancersMichael Cerniglia, Joanne Xiu, Axel Grothey, et al.
NPJ Precision Oncology|February 26, 2026
Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancerIbrahim Halil Sahin, Joanne Xiu, Yasmine Baca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
NPJ Precision Oncology|September 30, 2024
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancerJingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Clinical Lung Cancer|November 21, 2021
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung CancerMisako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
Cancer Cell|November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activationDavid Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
The Journal of Clinical Investigation|December 18, 2025
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtypeTimothy F Burns, Sanja Dacic, Anish Chakka, et al.
JCO Precision Oncology|April 28, 2025
Association of Androgen Receptor Expression With Tumor Immune Landscape and Treatment Outcomes of Patients With Breast CancerPriya Jayachandran, Sachin K Deshmukh, Sharon Wu, et al.
Iscience|March 27, 2023
Identification of actionable targets for breast cancer intervention using a diversity outbred mouse modelJennifer B Jacob, Kuang-Chung Wei, Gerold Bepler, et al.
European Urology|July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 TrialElizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Pageof 17